Delayed diagnosis of abdominal Henoch-Schonlein purpura in children:A case report

BACKGROUND For children with abdominal Henoch-Schonlein purpura presenting abdominal pain as an initial symptom and severe clinical manifestations,but without purpura appearance on the skin,the diagnosis and treatment are relatively difficult.This study summarized the characteristics of this group of patients by literature review and provided additional references for further refinement of glucocorticoid therapy in this vasculitis.CASE SUMMARY A 6-year-old girl presented mainly with repeated abdominal pain and had received short-term out-of-hospital treatment with hydrocortisone.On day 7 after onset,gastroscopy revealed chronic non-atrophic gastritis and erosive duodenitis without purpuric rash,and no obvious resolution of the abdominal pain was found after treatment against infection and for protection of gastric mucosa.On day 14 the inflammatory indices continued to rise and the pain was relieved after enhanced anti-infective therapy,but without complete resolution.On day 19,the patient presented with aggravated abdominal pain with purplish-red dots on the lower limbs,by which Henoch-Schonlein purpura was confirmed.After 5 d of sequential treatment with methylprednisolone and prednisone,abdominal pain disappeared and she was discharged.CONCLUSION Henoch-Schonlein purpura-related rash may appear after long-term abdominal pain,and should be distinguished from acute and chronic gastrointestinal diseases at the early stage without typical rash.For bacterial infection-induced Henoch-Schonlein purpura,glucocorticoid therapy alone without clearing the infection may not relieve symptoms.

Henoch-Schonlein purpura with intestinal perforation and cerebral hemorrhage: A case report

Henoch-Schonlein purpura (HSP) with intestinal perforation and cerebral hemorrhage is a very rare clinical condition. There has been no report of HSP complicated with both intestinal perforation and cerebral hemorrhage until October 2012. Here we describe a case of HSP with intestinal perforation and cerebral hemorrhage in a 5-year-old girl. Plain abdominal radiograph in the erect position showed heavy gas in the right subphrenic space with an elevated diaphragm. Partial resection of the small intestine was performed, and pathological analysis suggested chronic suppurative inflammation in all layers of the ileal wall and mesentery. Seventeen days after surgery, cerebral hemorrhage developed and the patient died.

Gastrointestinal manifestations of Henoch-Schonlein purpura: A report of two cases

Henoch-Schonlein purpura(HSP) is a small vessel vasculitis mediated by type Ⅲ hypersensitivity with deposition of Ig A immune complex in the walls of vessels. It is a multi-system disorder characterizedby palpable purpura, arthritis, glomerulonephritis and gastrointestinal manifestations and commonly occurs in children and young adults. The patients with gastrointestinal involvement usually present with colicky abdominal pain, vomiting and melena. The imaging findings include multifocal bowel thickening with mucosal hyperenhancement, presence of skip areas, mesenteric vascular engorgement, with involvement of unusual sites like stomach, duodenum and rectum. These imaging findings in a child or young adult with appropriate clinical findings could suggest HSP.

Henoch-Schonlein purpura from vasculitis to intestinal perforation: A case report and literature review

Henoch-Sch?nlein purpura(HSP) is generally a selflimited vasculitis disease and has a good prognosis. We report a 4-year-old Thai boy who presented with palpable purpura, abdominal colicky pain, seizure, and eventually developed intestinal ischemia and perforation despite adequate treatment, including corticosteroid and intravenous immunoglobulin therapy. Imaging modalities, including ultrasonography and contrastenhanced computed tomography, could not detect intestinal ischemia prior to perforation. In this patient, we also postulated that vasculitis-induced mucosal ischemia was a cause of the ulcer, leading to intestinal perforation, and high-dose corticosteroid could have been a contributing factor since the histopathology revealed depletion of lymphoid follicles. Intestinal perforation in HSP is rare, but life-threatening. Close monitoring and thorough clinical evaluation are essential to detect bowel ischemia before perforation, particularly in HSP patients who have hematochezia, persistent localized abdominal tenderness and guarding. In highly suspicious cases, exploratory laparotomy may be needed for the definite diagnosis and prevention of further complications.

Current views of the relationship between Helicobacter pylori and Henoch-Schonlein purpura in children

Helicobacter pylori(H. pylori) is one of the factors involved in the pathogenesis of various gastrointestinal diseases and may play a potential role in certain extraintestinal diseases. H. pylori infection are mainly acquired during childhood, and it has been reported that in endemic areas of China the infection rates are extraordinarily higher in HSP children, particular those with abdominal manifestations. Furthermore, eradication therapy may ameliorate Henoch-Schonlein purpura(HSP) manifestations and decrease the recurrence of HSP. Therefore, results suggested that detection of H. pylori infection by appropriate method ought to be applied in HSP children. Current evidences indicate that local injury of gastric mucosa and immunological events induced by H. pylori infection are involved in the development of HSP. Increased serum Ig A, cryoglobulins, C3 levels, autoimmunity, proinflammatory substances and molecular mimicry inducing immune complex and cross-reactive antibodies caused by H. pylori infection might play their roles in the course of HSP. However, there are no investigations confirming the causality between H. pylori infection and HSP, and the pathogenesis mechanism is still unclear. More bench and clinical studies need to be executed to elaborate the complex association between H. pylori and HSP.

Spectrum of Henoch-Schonlein Purpura in Children: A Single-Center Experience from Western Provence of Saudi Arabia

The aim of this study was to describe the common presentation, frequency, and complications of Henoch-Schonlein purpura (HSP) in patients <18 years who were followed up at King Abdulaziz University Hospital, Jeddah over the last 12 years. We performed a retrospective chart review of the medical records of all patients diagnosed as HSP. During this period, only 29 cases were reported (15 males, 14 females), with the mean age at the diagnosis 7.5 years. 82% percent of the patients had joint involvement in the form of arthritis or arthralgia;17.2% had no joint involvement. Abdominal manifestations were reported in 72.4% of the patients, while renal involvement was documented in 24.1% of the cases;two patients had scrotal involvement. Four patients (13.7%) had a recurrence within four months of HSP diagnosis. However, all patients had full recovery within a month. More research is warranted to study the prevalence, clinical manifestations, preceding factors, and complications of HSP in a Saudi-based cohort.

Effects of methylprednisolone combined with montelukast on immune function and cytokines in children with recurrent Henoch-Schonlein purpura

Objective:To study the effects of methylprednisolone combined with montelukast on immune function and cytokines in children with recurrent Henoch-Schonlein purpura.Methods:Children who were diagnosed with recurrent Henoch-Schonlein purpura in Zigong Third People's Hospital between September 2015 and August 2017 were selected as the research subjects and randomly divided into the intervention group who received methylprednisolone combined with montelukast therapy and the control group who received hydrocortisone therapy. The levels of Th1/Th2 and Th17/Treg immunity indexes in peripheral blood as well as cytokines in serum were measured before treatment as well as 4 and 8 weeks after treatment.Results: 4 weeks and 8 weeks after treatment, Th1 and Treg cell contents as well as T-bet and FoxP3 mRNA expression in peripheral blood of both groups of patients were significantly higher than those before treatment whereas Th2 and Th17 cell contents as well as GATA-3 and RORγt mRNA expression in peripheral blood and NF-κB, OPN, IL-33, MK and HMGB1 contents in serum were significantly lower than those before treatment, and Th1 and Treg cell contents as well as T-bet and FoxP3 mRNA expression in peripheral blood of intervention group were significantly higher than those of control group whereas Th2 and Th17 cell contents as well as GATA-3 and RORγt mRNA expression in peripheral blood and NF-κB, OPN, IL-33, MK and HMGB1 contents in serum were significantly lower than those of control group.Conclusion: methylprednisolone combined with montelukast treatment of recurrent Henoch-Schonlein purpura can regulate the immune function and inhibit the cytokine secretion.

Regularity of syndrome differentiation and treatment of traditional Chinese medicine for Henoch-Schonlein purpura based on data mining techniques

Objective:This study aims to explore the regularity of syndrome differentiation and treatment of traditional Chinese medicine(TCM)for allergic purpura.Methods:CNKI,Weipu Chinese science and technology database,wanfang medical network database,and Chinese biomedical literature database were searched for eligible studies.Medical records including complete patient personal information,patient symptoms,TCM syndromes,treatment,and medication were included.The data was analyzed using the Chinese medicine heritage support platform provided by the Chinese Academy of Chinese medicine(V2.5).Results:Differentiation of health gas camp blood was the most commonly used method of differentiation of symptoms and signs in famous veteran TCM.The treatment included cooling blood,activating blood circulation,clearing heat and detoxifying toxins,removing blood stasis and stopping bleeding.Honeysuckle,Forsythia suspensa,cicada slough and other drugs were interrelated.Potential drug pair combinations and drug networks showed the basic drug composition of Qingying Decoction.According to the entropy cluster analysis,28 core drug combination and 12 new formulations were obtained.Conclusion:The regularity of syndrome differentiation and treatment of traditional Chinese medicine for Henoch-Schonlein purpura based on the famous and old TCM doctors was complex.Further researches are still needed.

Evaluation of the cytokine levels and immune response status of montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura

Objective:To evaluate the cytokine levels and immune response status of montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura.Methods: A total of 80 patients with Henoch-Schonlein purpura who were treated in Ankang Central Hospital between May 2014 and January 2017 were collected and divided into montelukast group, loratadine group, tanshinone group and combined treatment group according to the random number table, 20 cases in each group. Serum levels of inflammatory factors, Th17/Treg cellular immunity indexes before and after treatment were compared among four groups of patients.Results: Before treatment, differences in serum levels of inflammatory factors and Th17/Treg cellular immunity indexes were not statistically significant among four groups of patients. After treatment, serum HMGB1, IL-8, IL-14, IL-23 and IL-33 levels in combined treatment group were lower than those in montelukast group, loratadine group and tanshinone group;serum IL-17 level was lower than that in montelukast group, loratadine group and tanshinone group while IL-10 and TGF-β levels were higher than those in montelukast group, loratadine group and tanshinone group.Conclusions: Montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura helps to reduce systemic inflammatory response and balance Th17/Treg cell immunity.

Overview of the pathogenesis of Henoch-Schonlein purpura in children and the research progress on related mechanism of inflammatory cytokines

Henoch-schonlein purpura (HSP) is a kind of systemic vasculitis that is common in childhood,and its pathogenesis is complicated and considered to have important relationship with lymphocytes, vascular endothelial cells and so on. The causes of this disease are complex and have not been clearly identified, but numerous studies have shown that inflammatory factors such as IL-1, IL-17 and TNF-α play an important role in the development of HSP.

Serum OPN and NF-κB contents in children with Henoch-Schonlein purpura and their correlation with oxidative stress and cellular immune function

Objective:To detect serum OPN and NF-κB contents in children with Henoch-Schonlein purpura (HSP) and study their correlation with oxidative stress and cellular immune function. Methods: The children who were diagnosed with HSP in Shijiazhuang First Hospital between February 2015 and October 2017 were selected as the HSP group of the study and the healthy children who received physical examination during the same period were selected as the control group. The serum was collected to measure the contents of OPN, NF-κB, oxidative stress indexes and immune cell inflammation, and the peripheral blood was collected to detect the mRNA expression of immune cell transcription factors.Results: OPN, NF-κB, MDA, MPO, IL-4, IL-5 and IL-17 contents in serum as well as GATA-3 and RORγt mRNA expression in peripheral blood of HSP group were significantly higher than those of control group whereas SOD, CAT, PON, IFN-γ and TGF-β1 contents in serum as well as T-bet and FoxP3 mRNA expression in peripheral blood were significantly lower than those of control group;serum OPN and NF-κB contents in HSP group were positively correlated with MDA, MPO, IL-4, IL-5 and IL-17 contents in serum as well as GATA-3 and RORγt mRNA expression in peripheral blood, and negatively correlated with SOD, CAT, PON, IFN-γand TGF-β1 contents in serum as well as T-bet and FoxP3 mRNA expression in peripheral blood. Conclusion: The abnormal increase of serum OPN and and NF-κB contents in children with HSP is closely related to the excessive oxidative stress activation and cellular immune dysfunction.

Effects of SOCS1 and SOCS3 in peripheral blood on CD4+T cell differentiation in children with Henoch-Schonlein purpura

Objective:To study the effects of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in peripheral blood on CD4+T cell differentiation in children with Henoch-Schonlein purpura. Methods: Children with Henoch-Schonlein purpura who were treated in Zigong Maternal and Child Health Hospital between June 2014 and February 2018 were selected as the HSP group of the study, and healthy children who received physical examination during the same period were selected as the control group of the study. Peripheral blood was collected to determine the expression of SOCS1 and SOCS3 as well as the contents of CD4+T cell subsets, and serum was collected to determine the contents of CD4+T cytokines.Results: SOCS1 and SOCS3 mRNA expression levels as well as SOCS3/SOCS1 ratio in peripheral blood of HSP group were significantly higher than those of control group;Th1 and Treg contents in peripheral blood as well as IFN-γ and TGF-β1 contents in serum of HSP group were lower than those of control group whereas Th2 and Th17 contents in peripheral blood as well as IL-4, IL-5 and IL-17 contents in serum were higher than those of control group, and Th1 and Treg contents in peripheral blood as well as IFN-γ and TGF-β1 contents in serum of HSP children with high SOCS3/SOCS1 ratio were lower than those of HSP children with low SOCS3/SOCS1 ratio whereas Th2 and Th17 contents in peripheral blood as well as IL-4, IL-5 and IL-17 contents in serum were higher than those of HSP children with low SOCS3/SOCS1 ratio.Conclusions: Changes in SOCS1 and SOCS3 expression in peripheral blood of children with Henoch-Schonlein purpura can affect the differentiation of CD4+T cells.

复方仙鹤颗粒治疗儿童难治性过敏性紫癜的临床研究

目的:观察复方仙鹤颗粒治疗难治性过敏性紫癜的临床疗效及其对免疫、炎症、凝血相关指标的影响。方法:将120例过敏性紫癜患儿,按照随机数字表法分为观察组和对照组,每组60例,两组患儿均给予西医常规治疗,在此基础上对照组口服槐杞黄颗粒,观察组加用复方仙鹤颗粒口服,连续治疗8周后评价两组患儿的疗效,观察两组患儿皮疹消退时间,复发次数,复发间隔时间,每2周检测尿常规;治疗前后两组患儿分别进行安全性指标(血常规、肝肾功能、电解质)、免疫相关指标(细胞因子、免疫球蛋白IgA、IgE)、炎性和凝血相关指标[C反应蛋白(CRP)、抗链球菌溶血素O(ASO)、D二聚体(D-D)]检测;并在6个月内进行随访,比较两组复发率。结果:观察组总有效率为86.7%,对照组为63.3%,观察组总有效率显著高于对照组(P<0.05)。与对照组相比,观察组治疗后皮疹持续时间缩短,复发次数减少、复发间隔时间更长(P<0.05);但两组患儿治疗后肾脏损伤改善比较无统计学意义(P>0.05)。治疗后,两组患者IL-2水平均高于治疗前,IL-4、IL-6、IL-10水平均低于治疗前(P<0.05),且治疗后观察组IL-2水平高于对照组,IL-4、IL-6、IL-10水平显著低于对照组(P<0.05),TNF-α水平两组之间差异无统计学意义(P>0.05);治疗后两组IgA水平均低于治疗前(P<0.05),且观察组IgA水平显著低于对照组(P<0.05),IgE水平两组之间差异无统计学意义(P>0.05);治疗后两组ASO、CRP、D-D水平均低于治疗前(P<0.05),且观察组ASO、CRP、D-D水平显著低于对照组(P<0.05);观察组复发率低于对照组(P<0.05)。结论:对于难治性过敏性紫癜,应用复方仙鹤颗粒联合西药治疗,临床疗效显著而且安全性好,特别是在治疗皮肤型过敏性紫癜较有优势,可缩短过敏性紫癜患者的皮疹持续时间,有效降低复发率,改善长期预后。作用机制可能与调节Th1/Th2免疫平衡,控制炎症反应,改善血液高凝状态有关。

Childhood Henoch-Schnlein Purpura Nephritis and IgA Nephropathy: One Disease Entity?——A Clinico-pathologically Comparative Study

Summary： In order to characterize their relationship through clinicopathological comparison between IgA nephropathy and Henoch-Schoenlein purpura nephritis （HSPN）, 31 children with IgA nephrop- athy aged between 3 to 15 years and 120 children with HSPN aged between 4 to 15 years were compared with each other in clinical manifestation, blood biochemistry, serum immunology and followup study. Renal pathological findings under light microscope, immunofluorescence and electronic microscope were analyzed and also compared between 31 children with IgA nephropathy and 32 biopsied children with HSPN. The results showed that the onset age was over 12 years in 25.8 % children with IgA nephropathy, but only 10 % in HSPN （P〈0.05）. The clinical patterns of IgA nephropathy and HSPN were similar, but extra-renal manifestations were more often in HSPN, all of them had skin purpura, 59 % had gastrointestinal symptoms and 47 % suffered from arthralgia, compared with only abdominal pain in 3.2 % children with IgA nephropathy. The renal pathological investigation showed global sclerosis in 35.5 % of IgA nephropathy and 3.1% of HSPN, mesangial sclerosis in 41.9 % of IgA nephropathy and 6.3 % of HSPN, but endothelial proliferation in 65.6 % of HSPN and 29 % of IgA nephropathy （all P〈0.01）. Thin basement membrane nephropathy was only found in 6. 5 % children with IgA nephropathy, no in HSPN. The electronic dense deposits in HSPN were sparse, lodse and wildly spread in glomerular mesangium, subendothelial area and even intra basement membrane, but it was dense, lumpy and mostly limited in mesangium and paramesangium in IgA nephropathy. Predominant IgA deposits were found in 81.2% of HSPN, and overwhelming IgG deposits in 12.5 % of HSPN with relatively weak IgA deposits, moreover 6.3 % of HSPN showed linear IgG deposits in glomerular capillary. Totally 71. 9 G of HSPN had IgG deposits in glomeruli and only 19.4% of IgA nephropathy showed glomerular IgG deposits （P〈0. 01）. No IgG deposit was observed in 81. 6 % of IgA nephropathy, among them most showed IgA and IgM and/or C3 deposits, moreover overwhelming IgG deposits and linear IgG deposits couldn＇t be found in IgA nephropathy. Mean 20 months follow-up showed complete remission in 72.5% of HSPN, but only 19.4% in IgA nephropathy after 34 months follow-up. Moreover, 64.5 % of IgA nephropathy had consistent hematuria and proteinuria and 16. 1% had active nephritides （P〈0.05）. It was concluded that significant clinico-pathological difference was found between HSPN and IgA nephropathy, which didn＇t support the one disease entity hypothesis. HSPN and IgA nephropathy are probably two diseases with similar immune abnormalities.

Expressions and significances of IFN-γ, IL-10, TGF-β, PFP and GNLY in serum of children with Henoch Schonlein purpura

Objective:To investigate the expressions of interferon-γ (IFN-γ), interleukin-10 (IL-10), transforming growth factor-β (TGF-β), perforin (PFP) and granulysin (GNLY) in serum of children with Henoch-Schonlein purpura (HSP) and their significances.Methods: 86 children with HSP admitted to our hospital from April 2016 to April 2018 were selected as the study subjects (HSP group), according to whether or not combined with renal injury, they were divided into kidney injury group (41 cases) and non-kidney injury group (45 cases), and 40 healthy children as the control group. The levels of serum IFN-γ, IL-10 and TGF-β were detected by enzyme-linked immunosorbent assay (ELISA), levels of serum PFP and GNLY were detected by RT-PCR, the differences between different groups were compared, the relationships between serum IFN-γ, IL-10, TGF-β, PFP and GNLY in group HSP was also analyzed.Results: The levels of serum IFN-γ, PFP and GNLY in HSP group were lower than those in control group (P<0.05), and the levels of serum IL-10 and TGF-β were higher than those in control group (P<0.05);the levels of serum IFN-γ, PFP and GNLY in renal injury group were lower than those in non-renal injury group (P<0.05), while the levels of serum IL-10 and TGF-β were higher than those in non-renal injury group (P<0.05);in HSP group, serum IFN-γ was negatively correlated with TGF-β (r=-0.417,P=0.037), and positively correlated with PFP and GNLY (r=0.508, 0.477,P=0.025, 0.030);there was a positive correlation between IL-10 and TGF-β (r=0.514,P=0.017).Conclusion: The changes of serum IFN-γ, IL-10, TGF-β, PFP and GNLY are closely related to the occurrence and progression of HSP, early detection is helpful to the evaluation of HSP and has guiding significance for clinical prevention of Henoch-Schonlein purpura nephritis.

沙利度胺联合二线方案治疗复发、难治性ITP患者的观察性研究

目的探讨沙利度胺联合二线方案治疗复发、难治性原发免疫性血小板减少症(ITP)患者的疗效及其对Th1/Th2细胞因子的影响。方法于2016年1月~2021年3月,将亳州市人民医院收治的86例复发、难治性ITP患者随机分为观察和对照2组,每组各43例患者。对照组给予地塞米松和利妥昔单抗治疗;观察组在对照组基础上给予沙利度胺口服。两组均于治疗12周评价疗效。比较治疗前与治疗12周出血评分、血小板计数(PLT)、Th1细胞因子[肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)和白介素-2(IL-2)]、Th2细胞因子[白介素-4(IL-4)和白介素-10(IL-10)]水平变化。结果观察组治疗总有效率为93.02%,明显高于对照组(72.09%)(P<0.05)。治疗12周,两组出血评分均低于治疗前(P<0.05),观察组出血评分明显低于对照组(P<0.001);观察组PLT计数明显高于对照组(P<0.001);两组血清TNF-α、IFN-γ和IL-2水平均明显低于治疗前(P<0.05),观察组明显低于对照组(P<0.001);血清IL-4和IL-10水平均明显高于治疗前(P<0.05),观察组明显高于对照组(P<0.001)。结论沙利度胺联合二线方案治疗复发难治性ITP患者临床疗效显著,且可调节Th1/Th2细胞因子水平。

以胸闷、胸痛为首发表现的难治性TTP一例

胸闷、胸痛是血栓性血小板减少性紫癜(TTP)极为罕见的首发临床表现,容易误诊为急性冠脉综合征,对于不明原因血小板减少和溶血性贫血的患者,鉴别诊断都应考虑TTP可能性,以免漏诊。对于TTP治疗应及时采取以血浆置换为主的综合治疗方法,积极寻找病因并对因治疗,是降低TTP早期死亡率的有效措施。本文报道一例以胸闷、胸痛为首发表现TTP病例的诊治资料,以提高对以非典型症状起病TTP的认识,减少误诊误治。

成人难治及复发ITP的个体化治疗及研究进展

免疫性血小板减少性紫癜(ITP)是血液系统的常见疾病,以出血、外周血血小板减少为主要临床特征。成人常呈慢性病程,其中11%-35%可发展为难治性ITP。调查研究显示,ITP发病与基因多态性有关。目前对于难治/复发性ITP的治疗还没有定论,从一定程度上说,其治疗依赖于患者的治疗需要和对治疗的反应。本综述的目的旨在为目前参差不齐的治疗策略提供临床参考。本文论述了难治/复发性ITP的所有治疗方案,并着重论述了新的疗法,包括抗CD20单克隆抗体、血小板生成素样物质、TPO受体激动剂和造血干细胞移植,在我国泛细胞保护剂也显示了较好的临床疗效。总之,最重要的是根据ITP患者的具体情况给予个体化治疗。

利妥昔单抗联合地塞米松治疗小儿难治性特发性血小板减少性紫癜临床效果观察

目的探讨应用利妥昔单抗(美罗华)联合地塞米松治疗儿童难治性特发性血小板减少性紫癜(RITP)的疗效及安全性。方法选择诊断为RITP的患儿22例,按照治疗方法不同分为对照组(大剂量地塞米松冲击治疗)和观察组(美罗华联合小剂量地塞米松治疗)。治疗结束后,对两组患儿进行疗效评价、观察记录药物不良反应,并应用流式细胞术测定11例观察组患儿治疗前后CD20+B细胞的数量变化。结果观察组临床疗效优于对照组,差异有显著性(P<0.05),治疗期间两组不良反应比较无明显差异,美罗华治疗后,有效组患儿外周血小板数量较治疗前明显升高,外周血CD20+B细胞数量较治疗前显著降低。结论美罗华联合地塞米松治疗RITP疗效确切,毒副作用较小。

中药联合重组白介素-11治疗难治性特发性血小板减少性紫癜的临床观察和护理

目的探讨中药联合重组白介素-11治疗难治性特发性血小板减少性紫癜的临床疗效和护理措施。方法将52例肾性贫血难治性特发性血小板减少性紫癜患者随机分成2组,治疗组26例给予重组人白介素-11(巨和粒)治疗,皮下注射,每天1次,连用14 d,每个月为1个疗程,并口服中药汤剂(由黄芪、生地、仙鹤草、水牛角、丹皮、紫珠草等组成),日1剂,早晚分服;对照组26例只给予重组人白介素-11(巨和粒)治疗。2组均配合专科护理干预措施,均治疗2个月。结果治疗组总有效率为88.5%,对照组为65.4%,2组比较差异有统计学意义(P<0.05)。结论中药联合重组白介素-Ⅱ对难治性特发性血小板减少性紫癜有显著疗效。